{
    "ticker": "ONCT",
    "name": "OncoSec Medical Incorporated",
    "description": "OncoSec Medical Incorporated is a biotechnology company focused on the development of innovative cancer immunotherapies. Founded in 2011 and headquartered in San Diego, California, OncoSec is dedicated to advancing the treatment of cancer through its proprietary technology, known as the OncoSec Delivery System. This system is designed to enhance the delivery of therapeutic agents directly into tumors, aiming to stimulate a robust immune response against cancer cells. The company's lead product candidate, KEYNOTE-695, is being evaluated in combination with pembrolizumab, an FDA-approved immune checkpoint inhibitor, for the treatment of patients with melanoma. OncoSec is also exploring other indications and combinations that could bolster its position in the oncology landscape. The company\u2019s mission is to provide patients with more effective treatment options that are less invasive and have fewer side effects compared to traditional therapies. By leveraging its cutting-edge technology and a strong pipeline, OncoSec aims to make significant strides in the field of cancer treatment, ultimately improving patient outcomes and quality of life.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2011",
    "website": "https://www.oncosec.com",
    "ceo": "Daniel O'Connor",
    "social_media": {
        "twitter": "https://twitter.com/OncoSec",
        "linkedin": "https://www.linkedin.com/company/oncosec-medical-incorporated/"
    },
    "investor_relations": "https://investors.oncosec.com",
    "key_executives": [
        {
            "name": "Daniel O'Connor",
            "position": "CEO"
        },
        {
            "name": "Michael P. McHugh",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Immunotherapy",
            "products": [
                "KEYNOTE-695",
                "OMS-141"
            ]
        }
    ],
    "seo": {
        "meta_title": "OncoSec Medical Incorporated | Innovative Cancer Immunotherapies",
        "meta_description": "Learn about OncoSec Medical Incorporated, a leader in developing innovative cancer immunotherapies using advanced delivery systems to improve treatment outcomes.",
        "keywords": [
            "OncoSec",
            "Cancer Immunotherapy",
            "Biotechnology",
            "Melanoma Treatment",
            "OMS-141"
        ]
    },
    "faq": [
        {
            "question": "What is OncoSec known for?",
            "answer": "OncoSec is known for developing innovative cancer immunotherapies and its proprietary OncoSec Delivery System."
        },
        {
            "question": "Who is the CEO of OncoSec?",
            "answer": "Daniel O'Connor is the CEO of OncoSec Medical Incorporated."
        },
        {
            "question": "Where is OncoSec headquartered?",
            "answer": "OncoSec is headquartered in San Diego, California, USA."
        },
        {
            "question": "What are OncoSec's main products?",
            "answer": "OncoSec's main products include KEYNOTE-695 and OMS-141, focusing on cancer treatment."
        },
        {
            "question": "When was OncoSec founded?",
            "answer": "OncoSec was founded in 2011."
        }
    ],
    "competitors": [
        "NK",
        "CLRB",
        "IMV",
        "APTX"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BMY",
        "NVS"
    ]
}